Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies

Philipp A. Ilinykh, Jessica Graber, Natalia A. Kuzmina, Kai Huang, Thomas Ksiazek, James E. Crowe, Alexander Bukreyev

Research output: Contribution to journalArticle

Abstract

Screening of monoclonal antibodies against ebolaviruses requires small-animal models. Wild-type mice require adaptation of ebolaviruses, whereas immunodeficient mice are still resistant to nonadapted Bundibugyo ebolavirus. Swapping of Ebola virus glycoprotein with that from Bundibugyo virus resulted in a replication-competent chimeric virus, which caused 100% lethal infection in STAT1 knockout mice. Monoclonal antibody BDBV223 isolated from a human survivor of Bundibugyo virus infection protected mice from challenge with the chimeric virus. These data demonstrate the suitability of the approach for in vivo screening of antibodies and suggest the greater contribution of internal Ebola proteins in pathogenesis compared to Bundibugyo virus proteins.

Original languageEnglish (US)
Pages (from-to)S418-S422
JournalThe Journal of infectious diseases
Volume218
Issue number5
DOIs
StatePublished - Nov 22 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies'. Together they form a unique fingerprint.

  • Cite this